1. CMU Intellectual Repository

Search


Current filters:




Start a new search
Add filters:

Use filters to refine the search results.

 | 
Results 1-10 of 13 (Search time: 0.004 seconds).
Item hits:
Issue DateTitleAuthor(s)
1-Aug-2013Tumor response and health-related quality of life in clinically selected patients from Asia with advanced non-small-cell lung cancer treated with first-line gefitinib: Post hoc analyses from the IPASS studyYi Long Wu; Masahiro Fukuoka; Tony S.K. Mok; Nagahiro Saijo; Sumitra Thongprasert; James C.H. Yang; Da Tong Chu; Jin Ji Yang; Yuri Rukazenkov
1-May-2013Impact of EGFR inhibitor in non-small cell lung cancer on progression-free and overall survival: A meta-analysisChee Khoon Lee; Chris Brown; Richard J. Gralla; Vera Hirsh; Sumitra Thongprasert; Chun Ming Tsai; Eng Huat Tan; James Chung Man Ho; Da Tong Chu; Adel Zaatar; Jemela Anne Osorio Sanchez; Vu Van Vu; Joseph Siu Kie Au; Akira Inoue; Siow Ming Lee; Val Gebski; James Chih Hsin Yang
20-Jul-2011Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non - small-cell lung cancer in Asia (IPASS)Masahiro Fukuoka; Yi Long Wu; Sumitra Thongprasert; Patrapim Sunpaweravong; Swan Swan Leong; Virote Sriuranpong; Tsu Yi Chao; Kazuhiko Nakagawa; Da Tong Chu; Nagahiro Saijo
1-Jan-2012A phase II study of sunitinib as a second-line treatment in advanced biliary tract carcinoma: A multicentre, multinational studyJun Ho Yi; Sumitra Thongprasert; Jeeyun Lee; D. C. Doval; Se Hoon Park; Joon Oh Park; Young Suk Park; Won Ki Kang; Ho Yeong Lim
10-Jun-2012Sunitinib plus erlotinib versus placebo plus erlotinib in patients with previously treated advanced non-small-cell lung cancer: A phase III trialGiorgio V. Scagliotti; Maciej Krzakowski; Aleksandra Szczesna; Janos Strausz; Anatoly Makhson; Martin Reck; Rafal F. Wierzbicki; Istvan Albert; Michael Thomas; Jose Elias Abrao Miziara; Zsolt S. Papai; Nina Karaseva; Sumitra Thongprasert; Elsa Dalmau Portulas; Joachim Von Pawel; Ke Zhang; Paulina Selaru; Lesley Tye; Richard C. Chao; Ramaswamy Govindan
1-Oct-2013Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from AsiaShukui Qin; Yuxian Bai; Ho Yeong Lim; Sumitra Thongprasert; Yee Chao; Jia Fan; Tsai Shen Yang; Vajarabhongsa Bhudhisawasdi; Won Ki Kang; Yu Zhou; Jee Hyun Lee; Yan Sun
1-Aug-2016Tumor marker analyses from the phase III, placebo-controlled, FASTACT-2 study of intercalated erlotinib with gemcitabine/platinum in the first-line treatment of advanced non-small-cell lung cancerTony Mok; Guia Ladrera; Vichien Srimuninnimit; Virote Sriuranpong; Chong Jen Yu; Sumitra Thongprasert; Jennifer Sandoval-Tan; Jin Soo Lee; Fatima Fuerte; David S. Shames; Barbara Klughammer; Matt Truman; Pablo Perez-Moreno; Yi Long Wu
15-Jul-2015Detection and dynamic changes of EGFR mutations from circulating tumor DNA as a predictor of survival outcomes in NSCLC Patients treated with first-line intercalated erlotinib and chemotherapyTony Mok; Yi Long Wu; Jin Soo Lee; Chong Jen Yu; Virote Sriuranpong; Jennifer Sandoval-Tan; Guia Ladrera; Sumitra Thongprasert; Vichien Srimuninnimit; Meilin Liao; Yunzhong Zhu; Caicun Zhou; Fatima Fuerte; Benjamin Margono; Wei Wen; Julie Tsai; Matt Truman; Barbara Klughammer; David S. Shames; Lin Wu
1-Jan-2017Efficacy and safety of first-line necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin in East Asian patients with stage IV squamous non-small cell lung cancer: A subgroup analysis of the phase 3, open-label, randomized SQUIRE studyKeunchil Park; Eun Kyung Cho; Maximino Bello; Myung Ju Ahn; Sumitra Thongprasert; Eun Kee Song; Victoria Soldatenkova; Henrik Depenbrock; Tarun Puri; Mauro Orlando
1-Feb-2017Efficacy according to blind independent central review: Post-hoc analyses from the phase III, randomized, multicenter, IPASS study of first-line gefitinib versus carboplatin/paclitaxel in Asian patients with EGFR mutation-positive advanced NSCLCYi Long Wu; Nagahiro Saijo; Sumitra Thongprasert; J. C.H. Yang; Baohui Han; Benjamin Margono; Busayamas Chewaskulyong; Patrapim Sunpaweravong; Yuichiro Ohe; Yukito Ichinose; Jin Ji Yang; Tony S.K. Mok; Helen Young; Vincent Haddad; Yuri Rukazenkov; Masahiro Fukuoka

Discover